Pancreatic Surgery vs TELLAPRIALBI Usage & Stats

This application for bed-side use helps in early recognition and management of complications in patients after pancreatic resection. Using routine information from clinical evaluation and blood tests it generates daily recommendations on abdominal computed tomography, antibiotic treatment, radiological drainage and abdominal drain removal. The algorithm of this application reduced major postoperative complications and mortality in a nationwide stepped-wedge randomized trial by the Dutch Pancreatic Cancer Group (DPCG) – Smits FJ et al – Lancet 2022. Disclaimer This Pancreatic surgary app contains information for healthcare professionals only, is not suitable for use by patients, and is not medical or treatment advice and should not be treated as such by the user. As such, this App should not be relied upon for medical diagnosis or as a recommendation for medical care or treatment. The information contained in this app is not a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images and information, on or available through this app is for general information purposes only for healthcare professionals. Professional medical advice and assistance We strongly encourage you to confirm any information obtained from or through this app with your doctor or other healthcare professional and to review any information related to a medical condition or treatment with your doctor or other healthcare professional.

Apple App Store
Free
Medical

Store Rank

- -

TELLAPRIALBI

The APRI and ALBI scores are commonly used in clinical routine to assess the severity of illness for patients suffering from hepatical tumors and to predict postoperative liver dysfunction after resection. Combining these scores, the APRI+ALBI score provides even better performance of assessment and prediction regarding 30-day-mortality after surgery. TELLAPRIALBI allows you to - enter relevant lab parameters (platelet count, AST, albumin and bilirubin levels) - automatically compute APRI, ALBI and APRI+ALBI scores for comparative review - select from a variety of tumor types together with the respective extent of resection and - view clinical interpretation plots regarding 30-day-mortality post operation highlighting the risk class indicated by the APRI+ALBI score. The app is intended for educational use by medical professionals and to allow review of the APRI+ALBI score and its predictive quality. All information entered into the app and computed by it is processed exclusively within the app on the users device and no information is stored, transmitted or shared by the app. TELLAPRIALBI was developed jointly by the Translational Experimental Liver Laboratory at the Medical University of Vienna (TELLVIENNA) and Howto Health GmbH. It is based on a joint research paper which is currently in print at BMJ Open. The app is published by and the service is provided by Howto Health GmbH.